Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-RISK-EVENT Study
2024-511950-35-00Phase 3Authorised
- Sponsor
- Medical University of Graz
- Start
- Jun 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3 trial of empagliflozin, colchicine and omega-3-acid triglycerides in myocardial infarction (MI), cardiac morbidity, heart failure (HF) and 2 more, sponsored by Medical University of Graz. Primary endpoint: Primary composite cardiovascular outcome. Planned start Jun 2025; status: authorised.
02
Drugs
empagliflozincolchicineomega-3-acid triglycerides
03
Conditions
myocardial infarction (MI)cardiac morbidityheart failure (HF)strokearteriosclerosis obliterans
Beyond the preview
Go deeper on 2024-511950-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511950-35-00.